CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
COSCIENS Biopharma Inc.
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026
$6.49+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $20.66M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
35.3%−1.3 pts over 5 years
Operating margin
-142.5%+13.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -21.8% | -19.9% | +15.5% | +30.0% | |
| Gross profit | -44.0% | -32.4% | +14.7% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 5.41 | 5.82 | 3.18 | |
| Interest coverage | – | – | -63.6× | |
| Inventory turnover | – | – | 2.4× | |
| Capex to revenue | 7.2% | – | 9.4% | |
| Diluted shares | 0M | 2M | 3M |
Where the cash went
Fiscal 2021 to 2025, five years combined
COSCIENS Biopharma generated $39.43M from operations and spent $2.92M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$39.43M
Used
$2.92M
Capital expenditure$2.92M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$8.47M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$8.47M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.32 → 3.18
- No dilutionShare count did not rise3M → 3M
- Gross margin improvedGross margin up on the prior year49.33% → 35.30%
- More efficientAsset turnover rose0.40 → 0.21